BACKGROUND AND PURPOSE: Patients with recurrent glioblastoma often exhibit regions
of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that …

BACKGROUND AND PURPOSE: Centrally restricted diffusion has been demonstrated in
recurrent high-grade gliomas treated with bevacizumab. Our purpose was to assess the …

BACKGROUND AND PURPOSE: A subset of patients with malignant glioma develops
conspicuous lesions characterized by persistent restricted diffusion during treatment with …

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor
progression in a patient with recurrent glioblastoma receiving bevacizumab. - Abstract …

Bevacizumab is an anti-vascular endothelial growth factor (VEGF) antibody with activity
against recurrent malignant glioma inducing high rates of objective responses as assessed …

Importance: With the increasing use of antiangiogenic agents in the treatment of high-grade
gliomas, we are becoming increasingly aware of distinctive imaging findings seen in a …

BACKGROUND AND PURPOSE: Most response criteria for patients with glioblastoma rely
on increases in the contrast enhancing abnormality to determine tumor progression. Our aim …

Objectives: To investigate the relevance of bevacizumab (BEV)-induced diffusion-restricted
lesions and T1-hyperintense lesions in patients with recurrent glioblastoma. Methods: We …

While patients with recurrent glioblastoma receiving anti-angiogenic therapy demonstrate
significant response rates, the benefit on patient survival is less clear. We assessed whether …

TO THE EDITOR: Therapy with bevacizumab results in high response rates in patients with
malignant glioma. 1 However, the mechanisms of action of bevacizumab are poorly …